Literature DB >> 29703913

Inflammatory breast cancer biology: the tumour microenvironment is key.

Bora Lim1,2, Wendy A Woodward3,4, Xiaoping Wang5,3, James M Reuben3,6, Naoto T Ueno7,8.   

Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive disease that accounts for ~2-4% of all breast cancers. However, despite its low incidence rate, IBC is responsible for 7-10% of breast cancer-related mortality in Western countries. Thus, the discovery of robust biological targets and the development of more effective therapeutics in IBC are crucial. Despite major international efforts to understand IBC biology, genomic studies have not led to the discovery of distinct biological mechanisms in IBC that can be translated into novel therapeutic strategies. In this Review, we discuss these molecular profiling efforts and highlight other important aspects of IBC biology. We present the intrinsic characteristics of IBC, including stemness, metastatic potential and hormone receptor positivity; the extrinsic features of the IBC tumour microenvironment (TME), including various constituent cell types; and lastly, the communication between these intrinsic and extrinsic components. We summarize the latest perspectives on the key biological features of IBC, with particular emphasis on the TME as an important contributor to the aggressive nature of IBC. On the basis of the current understanding of IBC, we hope to develop the next generation of translational studies, which will lead to much-needed survival improvements in patients with this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29703913     DOI: 10.1038/s41568-018-0010-y

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  86 in total

Review 1.  siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.

Authors:  Worapol Ngamcherdtrakul; Wassana Yantasee
Journal:  Transl Res       Date:  2019-08-19       Impact factor: 7.012

2.  Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Authors:  Naoto T Ueno; Savitri Krishnamurthy; Jennifer A Wargo; Elizabeth A Mittendorf; Sangeetha M Reddy; Alexandre Reuben; Souptik Barua; Hong Jiang; Shaojun Zhang; Linghua Wang; Vancheswaran Gopalakrishnan; Courtney W Hudgens; Michael T Tetzlaff; James M Reuben; Takahiro Tsujikawa; Lisa M Coussens; Khalida Wani; Yan He; Lily Villareal; Anita Wood; Arvind Rao; Wendy A Woodward
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

Review 3.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

Review 4.  Cancer progression and the invisible phase of metastatic colonization.

Authors:  Christoph A Klein
Journal:  Nat Rev Cancer       Date:  2020-10-06       Impact factor: 60.716

5.  Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer.

Authors:  Alan M Elder; Beth A J Tamburini; Lyndsey S Crump; Sarah A Black; Veronica M Wessells; Pepper J Schedin; Virginia F Borges; Traci R Lyons
Journal:  Cancer Res       Date:  2018-09-25       Impact factor: 12.701

Review 6.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

Review 7.  Rare Breast Cancer Subtypes.

Authors:  Sarah Jenkins; Megan E Kachur; Kamil Rechache; Justin M Wells; Stanley Lipkowitz
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

8.  The immune-related gene CD52 is a favorable biomarker for breast cancer prognosis.

Authors:  Yan-Fei Ma; Yongcheng Chen; Dalang Fang; Qianfang Huang; Zhizhai Luo; Qiang Qin; Jiayao Lin; Caihua Zou; Minyu Huang; Dongdong Meng; Qun Huang; Guan-Ming Lu
Journal:  Gland Surg       Date:  2021-02

9.  Intrapulmonary administration of purified NEIL2 abrogates NF-κB-mediated inflammation.

Authors:  Nisha Tapryal; Shandy Shahabi; Anirban Chakraborty; Koa Hosoki; Maki Wakamiya; Gobinda Sarkar; Gulshan Sharma; Victor J Cardenas; Istvan Boldogh; Sanjiv Sur; Gourisankar Ghosh; Tapas K Hazra
Journal:  J Biol Chem       Date:  2021-04-28       Impact factor: 5.157

10.  In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.

Authors:  Manasa Gadde; Caleb Phillips; Neda Ghousifam; Anna G Sorace; Enoch Wong; Savitri Krishnamurthy; Anum Syed; Omar Rahal; Thomas E Yankeelov; Wendy A Woodward; Marissa N Rylander
Journal:  Biotechnol Bioeng       Date:  2020-07-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.